SynthesisBMC infectious diseases2025
Prevalence of invasive fungal infection in critically Ill patients: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Empirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial.Acta anaesthesiologica Scandinavica · 2026Trial
- New Perspectives on Antimicrobial Agents: Fosmanogepix.Antimicrobial agents and chemotherapy · 2026Review
- N-terminal lipidation enhances membrane interaction and antifungal activity of a Trematocine-derived decapeptide.Applied microbiology and biotechnology · 2026Article
- Agricultural fungicides shape soil and sediment reservoirs of multidrug-resistant fungi.Nature communications · 2026Article
- An Evolving Challenge: Fungal Infections in the Contemporary ICU.Journal of fungi (Basel, Switzerland) · 2026Article
- Article
- Fast-tracking fungal detection: a rapid flow cytometric method for the detection of yeasts in blood cultures.Frontiers in microbiology · 2026Article
- MDR Bacteremia in the Critically Ill During COVID-19: The MARTINI Study.Pathogens (Basel, Switzerland) · 2025Observational
- Pathogen profile of co-infections and mortality determinants among patients with severe fever with thrombocytopenia syndrome.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive fungal infections (IFI) contribute significantly to morbidity and mortality among critically ill patients, particularly in intensive care units (ICUs). Accurate prevalence estimates are essential to inform clinical strategies. This study aimed to determine the prevalence of IFI, and assess regional and methodological variations.
methodsA systematic review and meta-analysis were conducted following PRISMA guidelines. Literature from PubMed, Scopus, Web of Science, and Cochrane Library were searched for observational studies published between 1999 and 2024. Inclusion criteria targeted studies reporting IFI prevalence in ICU populations. Data extraction and bias assessment were performed independently by two reviewers. A random-effects meta-analysis assessed pooled prevalence and heterogeneity (Cochran's Q and I2 statistics).
resultsOut of 2838 screened articles, 34 studies comprising 655,169 critically ill patients met inclusion criteria. The pooled prevalence of IFI was 5% (95% CI: 3-7%). Aspergillus spp. accounted for 10% and Candida spp. for 3%. Regional prevalence ranged from 3% in high-income countries to 21% in lower-middle-income countries. Diagnostic and methodological heterogeneity were notable contributors to variability.
conclusionsIFIs represent a significant burden in ICUs, particularly in resource-limited settings. Standardized diagnostic criteria and region-specific strategies are crucial to improving patient outcomes.
trial registrationPROSPERO ID CRD42023472191.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.